- Gives veterinarians a new choice for the treatment of
external and internal parasitic infestations
- Treats and has persistent efficacy against ticks and fleas
for one month
- Treats gastrointestinal nematodes
- Prevents heartworm disease (Dirofilaria immitis)
KIRKLAND, QC, Oct. 1, 2019 /CNW Telbec/ - Zoetis Inc. (NYSE:
ZTS) today announces that Simparica Trio™, a once-monthly
triple combination antiparasitic medication for dogs, receives
Notice of Compliance from Health Canada's Veterinary Drugs
Directorate.
"The approval of Simparica Trio™ provides veterinarians a safe and effective option for the treatment of external and
internal parasitic infestations in dogs in the form
of a new oral chewable," said Dr. Clotilde
Francis, DVM with Zoetis Canada. "Robust heartworm
protection was demonstrated in a recently published field study
with no dogs testing positive for adult heartworm infection when
dosed with the combination product.''(1)
"We are excited to bring Simparica Trio™ to veterinarians in
Canada as a new, effective triple
combination parasiticide for dogs," said Jair Garcia, Senior Vice President, Canada and Northern
Latin America at Zoetis. "This innovative product is a
result of the collaboration of Zoetis scientists worldwide, who
share a determination to develop new medicines that deliver real
value to our veterinary customers and the animals in their care.
The addition of this new, broad spectrum parasiticide to our
sarolaner range of products helps to tailor the antiparasitic
treatment of pets to their individual needs."
The global canine parasiticides market is more than $4 billion US dollars(2) and is the
largest therapeutic category in medicines for dogs.
Simparica Trio demonstrates Zoetis' continued innovation in
parasiticides
The active ingredients of Simparica Trio are:
sarolaner which is active against fleas and ticks; moxidectin
effective against heartworm and some intestinal worms; and pyrantel
pamoate, effective against certain gastrointestinal nematodes.
About internal and external parasites
Beyond being a
burden by feeding off the blood of infested dogs, fleas and ticks
can be carriers of vector borne diseases to other dogs which
can be very debilitating and difficult to treat. Larvae from
certain gastrointestinal worms may be shed in the environment and
pose a threat of zoonotic disease to humans while heartworm
(D.immitis) disease can be fatal to affected dogs.
(CPEP)(3)
About Zoetis
Zoetis is the leading animal health
company, dedicated to supporting its customers and their
businesses. Building on more than 65 years of experience in animal
health, Zoetis discovers, develops, manufactures and commercializes
medicines, vaccines and diagnostic products, which are complemented
by biodevices, genetic tests and a range of services. Zoetis serves
veterinarians, livestock producers and people who raise and care
for farm and companion animals with sales of its products in more
than 100 countries. In 2018, the company generated annual revenue
of $5.8 billion with approximately
10,000 employees. For more information, visit www.zoetis.com.
DISCLOSURE NOTICES
Forward-Looking Statements: This press release
contains forward-looking statements, which reflect the current
views of Zoetis with respect to business plans or prospects,
expectations regarding products, regulatory approvals and other
future events. These statements are not guarantees of future
performance or actions. Forward-looking statements are subject to
risks and uncertainties. If one or more of these risks or
uncertainties materialize, or if management's underlying
assumptions prove to be incorrect, actual results may differ
materially from those contemplated by a forward-looking statement.
Forward-looking statements speak only as of the date on which they
are made. Zoetis expressly disclaims any obligation to update or
revise any forward-looking statement, whether as a result of new
information, future events or otherwise. A further list and
description of risks, uncertainties and other matters can
be found in our Annual Report on Form 10-K for the
fiscal year ended December 31, 2018,
including in the sections thereof captioned "Forward-Looking
Statements and Factors That May Affect Future Results" and "Item
1A. Risk Factors," in our Quarterly Reports on Form 10-Q and in our
Current Reports on Form 8-K. These filings and subsequent filings
are available online at www.sec.gov, www.zoetis.com, or
on request from Zoetis.
1 https://parasitesandvectors.biomedcentral.com/articles/10.1186/s13071-019-3702-6
2 Based on internal estimates
3 Canadian Parasitology Expert Panel
Guidelines https://research-groups.usask.ca/cpep/index.php#Protocol
SOURCE Zoetis Inc.